{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:52:46Z","timestamp":1794743566048,"version":"4.9.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41571-025-01041-x","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T09:41:08Z","timestamp":1751881268000},"page":"680-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":189,"title":["EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja C.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Laane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-6591","authenticated-orcid":false,"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Raab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"1041_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard, F. et al. Multiple myeloma. Nat. Rev. Dis. Prim. 10, 45 (2024).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1041_CR2","doi-asserted-by":"publisher","first-page":"103193","DOI":"10.1016\/j.eclinm.2025.103193","volume":"83","author":"Sun","year":"2025","unstructured":"Sun, et al. Global landscape and trends in lifetime risks of haematologic malignancies in 185 countries: population-based estimates from GLOBOCAN 2022. eClinicalMedicine 83, 103193 (2025).","journal-title":"eClinicalMedicine"},{"key":"1041_CR3","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"1041_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood-2024-197908","volume":"144","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. Consolidation treatment with VRD followed by maintenance with lenalidomide in multiple myeloma improves overall survival: long-term follow-up of the EMN02\/HOVON95 randomized phase 3 trial. Blood 144, 674\u2013674 (2024).","journal-title":"Blood"},{"key":"1041_CR5","unstructured":"Surveillance, Epidemiology, and End Results Program. Cancer stat facts: myeloma. NIH https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (2024)."},{"key":"1041_CR6","first-page":"2420","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt, M., Kortum, K. M., Goldschmidt, H. & Merz, M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica 109, 2420\u20132435 (2024).","journal-title":"Haematologica"},{"key":"1041_CR7","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2217\/fon-2023-0021","volume":"19","author":"J Martinez-Lopez","year":"2023","unstructured":"Martinez-Lopez, J. et al. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 19, 2103\u20132121 (2023).","journal-title":"Future Oncol."},{"key":"1041_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00719-0","volume":"12","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar, S. V., Kumar, S., Lonial, S. & Mateos, M. V. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 12, 129 (2022).","journal-title":"Blood Cancer J."},{"key":"1041_CR9","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group.","year":"2003","unstructured":"International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol. 121, 749\u2013757 (2003).","journal-title":"Br. J. Haematol."},{"key":"1041_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","volume":"29","author":"S Thorsteinsd\u00f3ttir","year":"2023","unstructured":"Thorsteinsd\u00f3ttir, S. et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat. Med. 29, 467\u2013472 (2023).","journal-title":"Nat. Med."},{"key":"1041_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","volume":"32","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 309\u2013322 (2021).","journal-title":"Ann. Oncol."},{"key":"1041_CR12","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere 5, e528 (2021).","journal-title":"Hemasphere"},{"key":"1041_CR13","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino, M. et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J. Clin. Oncol. 40, 3406\u20133418 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR14","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01893","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau, H. et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J. Clin. Oncol., https:\/\/doi.org\/10.1200\/JCO-24-01893 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR16","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini, L. et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 3120\u20133131 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR17","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"JJ Garces","year":"2022","unstructured":"Garces, J. J. et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J. Clin. Oncol. 40, 3151\u20133161 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1200\/JCO.22.01606","volume":"41","author":"IV Kostopoulos","year":"2023","unstructured":"Kostopoulos, I. V. et al. Circulating plasma cells in newly diagnosed multiple myeloma: prognostic and more. J. Clin. Oncol. 41, 708\u2013710 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1002\/ajh.27414","volume":"99","author":"IV Kostopoulos","year":"2024","unstructured":"Kostopoulos, I. V. et al. Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma. Am. J. Hematol. 99, 1887\u20131896 (2024).","journal-title":"Am. J. Hematol."},{"key":"1041_CR20","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek, T. et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J. Clin. Oncol. 41, 1383\u20131392 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.annonc.2025.01.022","volume":"36","author":"P Musto","year":"2025","unstructured":"Musto, P. et al. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia. Ann. Oncol. 36, 361\u2013374 (2025).","journal-title":"Ann. Oncol."},{"key":"1041_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00587-0","volume":"11","author":"C Fernandez de Larrea","year":"2021","unstructured":"Fernandez de Larrea, C. et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 11, 192 (2021).","journal-title":"Blood Cancer J."},{"key":"1041_CR23","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1182\/bloodadvances.2021006762","volume":"6","author":"N Puig","year":"2022","unstructured":"Puig, N. et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 6, 3234\u20133239 (2022).","journal-title":"Blood Adv."},{"key":"1041_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00995-y","volume":"14","author":"HV Giles","year":"2024","unstructured":"Giles, H. V. et al. Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry. Blood Cancer J. 14, 50 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00803-z","volume":"13","author":"S Noori","year":"2023","unstructured":"Noori, S. et al. Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry. Blood Cancer J. 13, 30 (2023).","journal-title":"Blood Cancer J."},{"key":"1041_CR26","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood.2024024995","volume":"144","author":"N Puig","year":"2024","unstructured":"Puig, N. et al. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma. Blood 144, 2432\u20132438 (2024).","journal-title":"Blood"},{"key":"1041_CR27","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1038\/s41375-020-0750-z","volume":"34","author":"V Shah","year":"2020","unstructured":"Shah, V. et al. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia 34, 3091\u20133096 (2020).","journal-title":"Leukemia"},{"key":"1041_CR28","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget, S. et al. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat. Genet. 56, 1878\u20131889 (2024).","journal-title":"Nat. Genet."},{"key":"1041_CR29","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S2352-3026(17)30143-6","volume":"4","author":"M Bhutani","year":"2017","unstructured":"Bhutani, M. et al. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematol. 4, e443\u2013e451 (2017).","journal-title":"Lancet Haematol."},{"key":"1041_CR30","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"1041_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/bloodadvances.2023010821","volume":"8","author":"B Paiva","year":"2024","unstructured":"Paiva, B. et al. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma. Blood Adv. 8, 219\u2013223 (2024).","journal-title":"Blood Adv."},{"key":"1041_CR32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ajh.27582","volume":"100","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos, I. et al. Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials. Am. J. Hematol. 100, 427\u2013438 (2025).","journal-title":"Am. J. Hematol."},{"key":"1041_CR33","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren, O. et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144, 359\u2013367 (2024).","journal-title":"Blood"},{"key":"1041_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","volume":"6","author":"O Landgren","year":"2025","unstructured":"Landgren, O. & Devlin, S. M. Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap. Blood Cancer Discov. 6, 13\u201322 (2025).","journal-title":"Blood Cancer Discov."},{"key":"1041_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01102-x","volume":"14","author":"J Martinez-Lopez","year":"2024","unstructured":"Martinez-Lopez, J. et al. Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence. Blood Cancer J. 14, 131 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR36","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo, M. et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 18, e206\u2013e217 (2017).","journal-title":"Lancet Oncol."},{"key":"1041_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2214\/AJR.21.26381","volume":"218","author":"S Rama","year":"2022","unstructured":"Rama, S. et al. Comparative performance of whole-body MRI and FDG PET\/CT in evaluation of multiple myeloma treatment response: systematic review and meta-analysis. AJR Am. J. Roentgenol. 218, 602\u2013613 (2022).","journal-title":"AJR Am. J. Roentgenol."},{"key":"1041_CR38","doi-asserted-by":"publisher","first-page":"E230","DOI":"10.1002\/ajh.26995","volume":"98","author":"A Belotti","year":"2023","unstructured":"Belotti, A. et al. Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma. Am. J. Hematol. 98, E230\u2013E232 (2023).","journal-title":"Am. J. Hematol."},{"key":"1041_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2967\/jnumed.124.269393","volume":"66","author":"GA Ulaner","year":"2025","unstructured":"Ulaner, G. A., Lewis, J. & Landgren, O. CD38-targeted 89Zr-DFO-daratumumab PET of myeloma: immuno-PET impacting clinical care. J. Nucl. Med. 66, 482 (2025).","journal-title":"J. Nucl. Med."},{"key":"1041_CR40","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1200\/JCO.23.00934","volume":"42","author":"MC Pasquini","year":"2024","unstructured":"Pasquini, M. C. et al. Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival. J. Clin. Oncol. 42, 2757\u20132768 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman, B. A. et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 14, 170 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-209826","author":"E Terpos","year":"2024","unstructured":"Terpos, E. et al. Sustained MRD negativity for three years can guide discontinuation of lenalidomide maintenance after ASCT in multiple myeloma: results from a prospective cohort study. Blood https:\/\/doi.org\/10.1182\/blood-2024-209826 (2024).","journal-title":"Blood"},{"key":"1041_CR43","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1111\/ijlh.13460","volume":"43","author":"J Radocha","year":"2021","unstructured":"Radocha, J. et al. Urine immunofixation negativity is not necessary for complete response in intact immunoglobulin multiple myeloma: retrospective real-world confirmation. Int. J. Lab. Hematol. 43, e244\u2013e247 (2021).","journal-title":"Int. J. Lab. Hematol."},{"key":"1041_CR44","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1080\/10428194.2023.2201365","volume":"64","author":"KH Natsuhara","year":"2023","unstructured":"Natsuhara, K. H. et al. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma. Leuk. Lymphoma 64, 1186\u20131193 (2023).","journal-title":"Leuk. Lymphoma"},{"key":"1041_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"1041_CR46","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.6004\/jnccn.2020.7660","volume":"18","author":"T Schmidt","year":"2020","unstructured":"Schmidt, T. & Callander, N. Diagnosis and management of monoclonal gammopathy and smoldering multiple myeloma. J. Natl Compr. Canc Netw. 18, 1720\u20131729 (2020).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1041_CR47","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","volume":"174","author":"MV Mateos","year":"2022","unstructured":"Mateos, M. V. et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur. J. Cancer 174, 243\u2013250 (2022).","journal-title":"Eur. J. Cancer"},{"key":"1041_CR48","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR49","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","volume":"34","author":"CO Landgren","year":"2020","unstructured":"Landgren, C. O. et al. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 34, 1840\u20131852 (2020).","journal-title":"Leukemia"},{"key":"1041_CR50","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/blood.2024025897","volume":"145","author":"O Landgren","year":"2025","unstructured":"Landgren, O. et al. Efficacy and safety of daratumumab in intermediate\/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood 145, 1658\u20131669 (2025).","journal-title":"Blood"},{"key":"1041_CR51","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos, M. A. et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. New Engl. J. Med. 392, 1777\u20131788 (2025).","journal-title":"New Engl. J. Med."},{"key":"1041_CR52","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1200\/JCO.23.02771","volume":"42","author":"MV Mateos","year":"2024","unstructured":"Mateos, M. V. et al. Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance. J. Clin. Oncol. 42, 3247\u20133256 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR53","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","volume":"7","author":"D Kazandjian","year":"2021","unstructured":"Kazandjian, D. et al. Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial. JAMA Oncol. 7, 1678\u20131685 (2021).","journal-title":"JAMA Oncol."},{"key":"1041_CR54","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2022-168930","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar, S. K. et al. Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high risk smoldering multiple myeloma \u2013 results of the ascent trial [abstract]. Blood 140, 1830\u20131832 (2022).","journal-title":"Blood"},{"key":"1041_CR55","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301\u2013313 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR56","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1182\/blood.2024025746","volume":"145","author":"A Badros","year":"2025","unstructured":"Badros, A. et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood 145, 300\u2013310 (2025).","journal-title":"Blood"},{"key":"1041_CR57","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai, E. K. et al. Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J. Clin. Oncol. 43, 1279\u20131288 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR58","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau, P. et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 25, 1003\u20131014 (2024).","journal-title":"Lancet Oncol."},{"key":"1041_CR59","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau, C. et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood 143, 2029\u20132036 (2024).","journal-title":"Blood"},{"key":"1041_CR60","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa, L. J. et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J. Clin. Oncol. 40, 2901\u20132912 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt, L. B. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J. Clin. Oncol. 42, 26\u201337 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026230","author":"A Perrot","year":"2025","unstructured":"Perrot, A. et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial. Blood https:\/\/doi.org\/10.1182\/blood.2024026230 (2025).","journal-title":"Blood"},{"key":"1041_CR63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","volume":"142","author":"F Gay","year":"2023","unstructured":"Gay, F. et al. Results of the phase III randomized Iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients [abstract]. Blood 142, 4 (2023).","journal-title":"Blood"},{"key":"1041_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11507-9","volume":"23","author":"J Kauer","year":"2023","unstructured":"Kauer, J. et al. Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer 23, 1132 (2023).","journal-title":"BMC Cancer"},{"key":"1041_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70052","volume":"8","author":"EK Mai","year":"2024","unstructured":"Mai, E. K. et al. Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65\/GMMG-HD4 trial. Hemasphere 8, e70052 (2024).","journal-title":"Hemasphere"},{"key":"1041_CR66","doi-asserted-by":"publisher","first-page":"e816","DOI":"10.1016\/S2352-3026(24)00249-7","volume":"11","author":"G Cook","year":"2024","unstructured":"Cook, G. et al. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Haematol. 11, e816\u2013e829 (2024).","journal-title":"Lancet Haematol."},{"key":"1041_CR67","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","volume":"393","author":"MA Dimopoulos","year":"2019","unstructured":"Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393, 253\u2013264 (2019).","journal-title":"Lancet"},{"key":"1041_CR68","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosinol","year":"2023","unstructured":"Rosinol, L. et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood 142, 1518\u20131528 (2023).","journal-title":"Blood"},{"key":"1041_CR69","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","volume":"12","author":"A Krishnan","year":"2011","unstructured":"Krishnan, A. et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 12, 1195\u20131203 (2011).","journal-title":"Lancet Oncol."},{"key":"1041_CR70","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41375-019-0537-2","volume":"33","author":"S Knop","year":"2019","unstructured":"Knop, S. et al. Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. Leukemia 33, 2710\u20132719 (2019).","journal-title":"Leukemia"},{"key":"1041_CR71","first-page":"1469","volume":"109","author":"N Kroger","year":"2024","unstructured":"Kroger, N. et al. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study. Haematologica 109, 1469\u20131479 (2024).","journal-title":"Haematologica"},{"key":"1041_CR72","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"Facon","year":"2019","unstructured":"Facon et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 380, 2104\u20132115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR73","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos, M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 378, 518\u2013528 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR74","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"Durie","year":"2017","unstructured":"Durie et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389, 519\u2013527 (2017).","journal-title":"Lancet"},{"key":"1041_CR75","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon, T. et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 391, 1597\u20131609 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR76","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu, X. et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat. Med. 30, 2235\u20132241 (2024).","journal-title":"Nat. Med."},{"key":"1041_CR77","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani, S. Z. et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat. Med. 31, 1195\u20131202 (2025).","journal-title":"Nat. Med."},{"key":"1041_CR78","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","volume":"26","author":"MV Mateos","year":"2025","unstructured":"Mateos, M. V. et al. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 26, 596\u2013608 (2025).","journal-title":"Lancet Oncol."},{"key":"1041_CR79","doi-asserted-by":"publisher","first-page":"pe24","DOI":"10.1126\/sageke.2005.31.pe24","volume":"2005","author":"LP Fried","year":"2005","unstructured":"Fried, L. P. et al. From bedside to bench: research agenda for frailty. Sci. Aging Knowl. Env. 2005, pe24 (2005).","journal-title":"Sci. Aging Knowl. Env."},{"key":"1041_CR80","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41375-020-0918-6","volume":"34","author":"G Cook","year":"2020","unstructured":"Cook, G., Larocca, A., Facon, T., Zweegman, S. & Engelhardt, M. Defining the vulnerable patient with myeloma \u2013 a frailty position paper of the European Myeloma Network. Leukemia 34, 2285\u20132294 (2020).","journal-title":"Leukemia"},{"key":"1041_CR81","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/j.1532-5415.2012.04054.x","volume":"60","author":"RM Collard","year":"2012","unstructured":"Collard, R. M. et al. Prevalence of frailty in community-dwelling older persons: a systematic review. J. Am. Geriatr. Soc. 60, 1487\u20131492 (2012).","journal-title":"J. Am. Geriatr. Soc."},{"key":"1041_CR82","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt, M. et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102, 910\u2013921 (2017).","journal-title":"Haematologica"},{"key":"1041_CR83","doi-asserted-by":"publisher","first-page":"e729","DOI":"10.1016\/S2666-7568(22)00218-5","volume":"3","author":"G Cook","year":"2022","unstructured":"Cook, G., Pawlyn, C., Cairns, D. A. & Jackson, G. H. Defining FiTNEss for treatment for multiple myeloma. Lancet Healthy Longev. 3, e729\u2013e730 (2022).","journal-title":"Lancet Healthy Longev."},{"key":"1041_CR84","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Geriatric assessment predicts survival and toxicities in elderlymyeloma patients: an International Myeloma Working Group report. Blood 125, 2068\u20132074 (2015).","journal-title":"Blood"},{"key":"1041_CR85","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1080\/10428194.2024.2340052","volume":"65","author":"I Haider","year":"2024","unstructured":"Haider, I. et al. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL). Leuk. Lymphoma 65, 1167\u20131174 (2024).","journal-title":"Leuk. Lymphoma"},{"key":"1041_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.102051","volume":"15","author":"A Gahagan","year":"2024","unstructured":"Gahagan, A. et al. Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma. J. Geriatr. Oncol. 15, 102051 (2024).","journal-title":"J. Geriatr. Oncol."},{"key":"1041_CR87","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/imj.16049","volume":"53","author":"S Sim","year":"2023","unstructured":"Sim, S. et al. The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia. Intern. Med. J. 53, 819\u2013824 (2023).","journal-title":"Intern. Med. J."},{"key":"1041_CR88","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon, T. et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 34, 224\u2013233 (2020).","journal-title":"Leukemia"},{"key":"1041_CR89","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","volume":"6","author":"G Cook","year":"2019","unstructured":"Cook, G. et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance risk profile): a development and validation study. Lancet Haematol. 6, e154\u2013e166 (2019).","journal-title":"Lancet Haematol."},{"key":"1041_CR90","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood-2024-209653","volume":"144","author":"G Cook","year":"2024","unstructured":"Cook, G. et al. IMWG frailty score-adjusted therapy delivery reduces the early mortality risk in newly diagnosed TNE multiple myeloma: results of the UK Myeloma ResearchAlliance (UK-MRA) myeloma XIV fitness trial [abstract]. Blood 144, 673 (2024).","journal-title":"Blood"},{"key":"1041_CR91","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon, T. et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia 36, 1066\u20131077 (2022).","journal-title":"Leukemia"},{"key":"1041_CR92","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2024-203045","volume":"144","author":"S Manier","year":"2024","unstructured":"Manier, S. et al. The IFM2017-03 phase 3 trial: a dexamethasone sparing-regimen with daratumumab and lenalidomide for frail patients with newly-diagnosed multiple myeloma [abstract]. Blood 144, 774\u2013775 (2024).","journal-title":"Blood"},{"key":"1041_CR93","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","volume":"12","author":"FB Askeland","year":"2025","unstructured":"Askeland, F. B. et al. Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 12, e120\u2013e127 (2025).","journal-title":"Lancet Haematol."},{"key":"1041_CR94","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 391, 393\u2013407 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR95","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2024-200336","volume":"144","author":"V Hungria","year":"2024","unstructured":"Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 dreamm-7 trial [abstract]. Blood 144, 772 (2024).","journal-title":"Blood"},{"key":"1041_CR96","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR97","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/blood-2024-201533","volume":"144","author":"R Popat","year":"2024","unstructured":"Popat, R. et al. Ciltacabtagene autoleucel (Cilta-cel) vs standard of care (SoC) in patients with lenalidomide (Len)-refractory multiple myeloma (MM) after 1-3 lines of therapy: minimal residual disease (MRD) negativity in the phase 3 Cartitude-4 trial [abstract]. Blood 144, 1032 (2024).","journal-title":"Blood"},{"key":"1041_CR98","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2403407","volume":"391","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M. A. et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N. Engl. J. Med. 391, 408\u2013421 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR99","doi-asserted-by":"publisher","first-page":"LBA105","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA105","volume":"42","author":"S Trudel","year":"2024","unstructured":"Trudel, S. et al. Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM) [abstract]. J. Clin. Oncol. 42, LBA105 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR100","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki, S. et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet 396, 1563\u20131573 (2020).","journal-title":"Lancet"},{"key":"1041_CR101","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/ejh.14223","volume":"113","author":"MV Mateos","year":"2024","unstructured":"Mateos, M. V. et al. Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial. Eur. J. Haematol. 113, 242\u2013252 (2024).","journal-title":"Eur. J. Haematol."},{"key":"1041_CR102","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","volume":"34","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou, M. et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 34, 2430\u20132440 (2020).","journal-title":"Leukemia"},{"key":"1041_CR103","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/10428194.2024.2322030","volume":"65","author":"A Perrot","year":"2024","unstructured":"Perrot, A. et al. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk. Lymphoma 65, 833\u2013842 (2024).","journal-title":"Leuk. Lymphoma"},{"key":"1041_CR104","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000786","volume":"6","author":"P Sonneveld","year":"2022","unstructured":"Sonneveld, P. et al. Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. Hemasphere 6, e786 (2022).","journal-title":"Hemasphere"},{"key":"1041_CR105","doi-asserted-by":"publisher","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"M Cavo","year":"2020","unstructured":"Cavo, M. et al. Autologous haematopoietic stem-cell transplantation versus bortezomib\u2013melphalan\u2013prednisone, with or without bortezomib\u2013lenalidomide\u2013dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Hematol. 7, e456\u2013e468 (2020).","journal-title":"Lancet Hematol."},{"key":"1041_CR106","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 801\u2013812 (2021).","journal-title":"Lancet Oncol."},{"key":"1041_CR107","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial. Lancet Haematol. 10, e813\u2013e824 (2023).","journal-title":"Lancet Haematol."},{"key":"1041_CR108","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000975","volume":"7","author":"E Kastritis","year":"2023","unstructured":"Kastritis, E. et al. Management and outcomes of anti-CD38 refractory patients: the impact of retreatment and of subsequent therapies. Hemasphere 7, e975 (2023).","journal-title":"Hemasphere"},{"key":"1041_CR109","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","volume":"7","author":"O Perez de Acha","year":"2023","unstructured":"Perez de Acha, O. et al. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Adv. 7, 6430\u20136440 (2023).","journal-title":"Blood Adv."},{"key":"1041_CR110","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani, S. Z. et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 7, 3739\u20133748 (2023).","journal-title":"Blood Adv."},{"key":"1041_CR111","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/ajh.27206","volume":"99","author":"E Terpos","year":"2024","unstructured":"Terpos, E. et al. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA. Am. J. Hematol. 99, 396\u2013407 (2024).","journal-title":"Am. J. Hematol."},{"key":"1041_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104084","volume":"10","author":"EA Martino","year":"2025","unstructured":"Martino, E. A. et al. Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients. ESMO Open. 10, 104084 (2025).","journal-title":"ESMO Open."},{"key":"1041_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01134-3","volume":"14","author":"RD Parrondo","year":"2024","unstructured":"Parrondo, R. D. et al. Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma. Blood Cancer J. 14, 152 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR114","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"1041_CR115","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR116","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR117","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR118","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi, S. et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood 144, 2389\u20132401 (2024).","journal-title":"Blood"},{"key":"1041_CR119","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR120","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall, A. L. et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma [abstract]. J. Clin. Oncol. 42, 7540 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR121","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"1041_CR122","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1182\/blood-2024-208192","volume":"144","author":"HM Prince","year":"2024","unstructured":"Prince, H. M. et al. MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of elranatamab in patients with relapsed or refractory multiple myeloma [abstract]. Blood 144, 4738 (2024).","journal-title":"Blood"},{"key":"1041_CR123","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma, N. et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J. Clin. Oncol. 42, 2702\u20132712 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR124","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1041_CR125","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari, A. et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. Lancet Hematol. 12, e269\u2013e281 (2025).","journal-title":"Lancet Hematol."},{"key":"1041_CR126","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/JCO.20.02259","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson, P. G. et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J. Clin. Oncol. 39, 757\u2013767 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR127","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3026(21)00381-1","volume":"9","author":"FH Schjesvold","year":"2022","unstructured":"Schjesvold, F. H. et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 9, e98\u2013e110 (2022).","journal-title":"Lancet Haematol."},{"key":"1041_CR128","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa, L. J. et al. International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia 39, 543\u2013554 (2025).","journal-title":"Leukemia"},{"key":"1041_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri, C. J. et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 13, 117 (2023).","journal-title":"Blood Cancer J."},{"key":"1041_CR130","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen, A. D. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141, 219\u2013230 (2023).","journal-title":"Blood"},{"key":"1041_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01197-2","volume":"14","author":"M Merz","year":"2024","unstructured":"Merz, M. et al. Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy. Blood Cancer J. 14, 214 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR132","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/JCO.2023.41.16_suppl.8008","volume":"41","author":"AK Nooka","year":"2023","unstructured":"Nooka, A. K. et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies [abstract]. J. Clin. Oncol. 41, 8008 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR133","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau, C. et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood 144, 2375\u20132388 (2024).","journal-title":"Blood"},{"key":"1041_CR134","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","volume":"133","author":"E Terpos","year":"2019","unstructured":"Terpos, E., Ntanasis-Stathopoulos, I. & Dimopoulos, M. A. Myeloma bone disease: from biology findings to treatment approaches. Blood 133, 1534\u20131539 (2019).","journal-title":"Blood"},{"key":"1041_CR135","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol. 22, e119\u2013e130 (2021).","journal-title":"Lancet Oncol."},{"key":"1041_CR136","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","volume":"100","author":"E Terpos","year":"2015","unstructured":"Terpos, E. et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica 100, 1254\u20131266 (2015).","journal-title":"Haematologica"},{"key":"1041_CR137","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","volume":"36","author":"K Anderson","year":"2018","unstructured":"Anderson, K. et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 36, 812\u2013818 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR138","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje, N. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 19, 370\u2013381 (2018).","journal-title":"Lancet Oncol."},{"key":"1041_CR139","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","volume":"5","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood Adv. 5, 725\u2013736 (2021).","journal-title":"Blood Adv."},{"key":"1041_CR140","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood-2024-202539","volume":"144","author":"E Terpos","year":"2024","unstructured":"Terpos, E. et al. Evaluation of the safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment; results from an IMWG Bone Subcommittee study [abstract]. Blood 144, 3343\u20133344 (2024).","journal-title":"Blood"},{"key":"1041_CR141","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1182\/blood-2013-04-498139","volume":"122","author":"A Larocca","year":"2013","unstructured":"Larocca, A. et al. The impact of response on bone-directed therapy in patients with multiple myeloma. Blood 122, 2974\u20132977 (2013).","journal-title":"Blood"},{"key":"1041_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01046-2","volume":"14","author":"T Lund","year":"2024","unstructured":"Lund, T. et al. In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease. Blood Cancer J. 14, 65 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR143","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ctrv.2009.08.002","volume":"35","author":"E Katodritou","year":"2009","unstructured":"Katodritou, E. et al. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. Cancer Treat. Rev. 35, 738\u2013743 (2009).","journal-title":"Cancer Treat. Rev."},{"key":"1041_CR144","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1053\/j.seminhematol.2009.01.005","volume":"46","author":"E Terpos","year":"2009","unstructured":"Terpos, E. et al. Management of complications in multiple myeloma. Semin. Hematol. 46, 176\u2013189 (2009).","journal-title":"Semin. Hematol."},{"key":"1041_CR145","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3324\/haematol.2014.107714","volume":"100","author":"C Blimark","year":"2015","unstructured":"Blimark, C. et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100, 107\u2013113 (2015).","journal-title":"Haematologica"},{"key":"1041_CR146","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje, N. S. et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 9, e143\u2013e161 (2022).","journal-title":"Lancet Haematol."},{"key":"1041_CR147","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","volume":"35","author":"H Ludwig","year":"2021","unstructured":"Ludwig, H. et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 35, 31\u201344 (2021).","journal-title":"Leukemia"},{"key":"1041_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje, N. et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 13, 116 (2023).","journal-title":"Blood Cancer J."},{"key":"1041_CR149","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson, M. T. et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 20, 1760\u20131772 (2019).","journal-title":"Lancet Oncol."},{"key":"1041_CR150","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol. 24, e293\u2013e311 (2023).","journal-title":"Lancet Oncol."},{"key":"1041_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0110-7","volume":"8","author":"J Mikhael","year":"2018","unstructured":"Mikhael, J. et al. Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood Cancer J. 8, 86 (2018).","journal-title":"Blood Cancer J."},{"key":"1041_CR152","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/annonc\/mdt483","volume":"25","author":"MA Dimopoulos","year":"2014","unstructured":"Dimopoulos, M. A. et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann. Oncol. 25, 195\u2013200 (2014).","journal-title":"Ann. Oncol."},{"key":"1041_CR153","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1111\/bjh.16286","volume":"190","author":"MJ Cejalvo","year":"2020","unstructured":"Cejalvo, M. J. et al. Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. Br. J. Haematol. 190, e289\u2013e292 (2020).","journal-title":"Br. J. Haematol."},{"key":"1041_CR154","doi-asserted-by":"publisher","first-page":"E226","DOI":"10.1002\/ajh.27001","volume":"98","author":"E Kastritis","year":"2023","unstructured":"Kastritis, E. et al. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed\/refractory multiple myeloma and severe renal impairment or on dialysis: the DARE study. Am. J. Hematol. 98, E226\u2013E229 (2023).","journal-title":"Am. J. Hematol."},{"key":"1041_CR155","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00277-023-05163-z","volume":"102","author":"R Wasch","year":"2023","unstructured":"Wasch, R. et al. Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis. Ann. Hematol. 102, 1269\u20131270 (2023).","journal-title":"Ann. Hematol."},{"key":"1041_CR156","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.1002\/ajh.27063","volume":"98","author":"L Joiner","year":"2023","unstructured":"Joiner, L., Bal, S., Godby, K. N. & Costa, L. J. Teclistamab in patients with multiple myeloma and impaired renal function. Am. J. Hematol. 98, E322\u2013E324 (2023).","journal-title":"Am. J. Hematol."},{"key":"1041_CR157","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/bjh.19772","volume":"205","author":"P Lebreton","year":"2024","unstructured":"Lebreton, P. et al. Teclistamab for relapsed refractory multiple myeloma patients on dialysis. Br. J. Haematol. 205, 2077\u20132079 (2024).","journal-title":"Br. J. Haematol."},{"key":"1041_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00494-4","volume":"11","author":"S Lonial","year":"2021","unstructured":"Lonial, S. et al. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 11, 103 (2021).","journal-title":"Blood Cancer J."},{"key":"1041_CR159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7512","author":"E Terpos","year":"2025","unstructured":"Terpos, E. et al. Belantamab mafodotin plus lenalidomide\/dexamethasone in newly diagnosed intermediate-fit and frail multiple myeloma patients: long-term efficacy and safety from the phase 1\/2 BELARD clinical trial [abstract]. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7512 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1041_CR160","doi-asserted-by":"publisher","first-page":"eaax8861","DOI":"10.1126\/scitranslmed.aax8861","volume":"11","author":"J Li","year":"2019","unstructured":"Li, J. et al. CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity. Sci. Transl. Med. 11, eaax8861 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1041_CR161","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig, H. et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 24, e255\u2013e269 (2023).","journal-title":"Lancet Oncol."},{"key":"1041_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1392831","volume":"15","author":"MW Han","year":"2024","unstructured":"Han, M. W. et al. Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis. Front. Neurol. 15, 1392831 (2024).","journal-title":"Front. Neurol."},{"key":"1041_CR163","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 34, 45\u201355 (2019).","journal-title":"Blood Rev."},{"key":"1041_CR164","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."},{"key":"1041_CR165","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099\u20132103 (2021).","journal-title":"Nat. Med."},{"key":"1041_CR166","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85\u201396 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1041_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa, B. A. et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 14, 84 (2024).","journal-title":"Blood Cancer J."},{"key":"1041_CR168","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","volume":"20","author":"SS Jatiani","year":"2020","unstructured":"Jatiani, S. S. et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin. Lymphoma Myeloma Leuk. 20, 632\u2013636.e1 (2020).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1041_CR169","doi-asserted-by":"publisher","first-page":"132","DOI":"10.6004\/jnccn.2025.0023","volume":"23","author":"SK Kumar","year":"2025","unstructured":"Kumar, S. K. et al. NCCN guidelines insights: multiple myeloma, version 1.2025. J. Natl Compr. Canc Netw. 23, 132\u2013140 (2025).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"1041_CR170","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/clinids\/18.3.421","volume":"18","author":"PA Gross","year":"1994","unstructured":"Gross, P. A. et al. Purpose of quality standards for infectious diseases. Clin. Infect. Dis. 18, 421 (1994).","journal-title":"Clin. Infect. Dis."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01041-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01041-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:15:35Z","timestamp":1757207735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-025-01041-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":170,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1041"],"URL":"https:\/\/doi.org\/10.1038\/s41571-025-01041-x","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"5 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, Mario Boccadoro (University of Torino, Turin, Italy) was listed with an incorrect second affiliation, which is now removed in the HTML and PDF versions of the article.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.D. has received honoraria as a consultant, or member of the advisory board or speaker\u2019s bureau for Amgen, AstraZeneca, Beigene, BMS, GSK, Janssen, Menarini, Regeneron, Sanofi, Swixx and Takeda. E.T. has been a member of the advisory board for Amgen, AstraZeneca, BMS, EUSA Pharma, GSK, Johnson & Johnson, Menarini, Pfizer, Sanofi and Takeda; has received honoraria from Amgen, Antengene, AstraZeneca, BMS, EUSA Pharma, Forus, GSK, Johnson & Johnson, Menarini, Novartis, Pfizer, Sanofi, Swixx and Takeda; research funding from Amgen, GSK, Johnson & Johnson, Sanofi and Takeda; and travel expenses from Takeda. M.Bo. has received honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Novartis and Sanofi; has been a member of the advisory board for GSK and Janssen; and has received research funding from Amgen, BMS, Celgene, Janssen, Mundipharma, Novartis and Sanofi. P.M. has received honoraria as a member of the advisory board for Abbvie, Amgen, BMS, Johnson & Johnson, Pfizer, Sanofi and Takeda. M.-V.M. has received honoraria as a member of the advisory board for Abbvie, Amgen, BMS, GSK, Johnson & Johnson, Kite, Menarini, Oncopeptides, Pfizer, Roche and Sanofi. S.Z. has received research support from Janssen and Takeda; and has been a member of the advisory board for BMS, Janssen, Sanofi and Oncopeptides, for which she received no personal funding. G.C. has received research funding from BMS, Johnson & Johnson and Takeda, BMS; acted as a paid consultant for AstraZeneca, Johnson & Johnson, Menarini and Pfizer; and acted as a member of the speaker\u2019s bureau for Johnson & Johnson, Menarini and Pfizer. M.E. has been a member of the advisory board for BMS, GSK, Janssen, Menarini, Oncopeptides, Pfizer, Sanofi; and received honoraria from Abbvie, BMS, GSK, Janssen, Menarini, Oncopeptides, Pfizer and Sanofi. M.D. has received honoraria as a member of the advisory board or speaker\u2019s bureau for AbbVie, Amgen, BMS, GSK, Johnson & Johnson, Menarini, Pfizer, Roche and Sanofi; and works for an institution that receives grants from Johnson & Johnson. R.H. has been a consultant or member of the advisory board for Abbvie, Amgen, BMS, Celgene, Janssen, Novartis, PharmaMar and Takeda; has received honoraria from Amgen, BMS, Celgene, Janssen, PharmaMar and Takeda; and has received research funding from Amgen, BMS, Celgene, Janssen, Novartis and Takeda. F.S. has been a consultant for AbbVie, BMS, Celgene, GSK, Johnson & Johnson, Oncopeptides, Sanofi and Takeda; has received honoraria from AbbVie, Amgen, BMS, Celgene, Daiichi\u2013Sankyo, GSK, Johnson & Johnson, Novartis, Oncopeptides, Sanofi, Schain, SkylineDx, Skylite and Takeda; and has received research funding from Celgene, GSK, Johnson & Johnson, Oncopeptides, Sanofi and Targovax. F.G. has been a member of the advisory board for Abbvie, Amgen, AstraZeneca, BMS, Celgene, GSK, Janssen, Kite, Pfizer, Regeneron, Roche Pharma, Sanofi and Takeda; and has received honoraria from Abbvie, BMS, Celgene, Janssen, Menarini, Pfizer, Regeneron, Roche, Sanofi and Takeda. S.M. has been a consultant for Abbvie, Adaptive Biotechnology, Amgen, BMS, Celgene, GSK, Janssen, Kite, Novartis, Pfizer, Regeneron, Roche, Sanofi and Takeda. K.C.W. has had an advisory role or provided expert testimony for Abbvie, Adaptive, Amgen, AstraZeneca, Beigene, BMS, Celgene, GSK, Janssen, Karyopharm, Menarini, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda; has received honoraria from Abbvie, Adaptive, Amgen, AstraZeneca, Beigene, BMS, Celgene, GSK, Janssen, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda; and has received research funding from Abbvie, Amgen, BMS, Celgene, GSK, Janssen and Sanofi. M.K. has had an advisory role or provided expert testimony for Abbvie, Adaptive, BMS, Celgene, GSK, Janssen, Pfizer, Regeneron, Roche, Sanofi and Takeda; and works for an institution that has received research support from BMS, Celgene and Janssen. N.W.C.J.v.d.D. has received research support from Amgen, BMS, Celgene, Cellectis, Janssen and Novartis; and has been a member of the advisory board for AbbVie, Adaptive, Amgen, Bayer, BMS, Celgene, Janssen, Kite, Merck, Novartis, Pfizer, Roche, Sanofi, Servier and Takeda; all these roles have been paid to his institution. E.Z. has received honoraria as a member of the advisory board for Amgen, BMS, GSK, Janssen, Menarini, Pfizer, Oncopeptides and Sanofi. P.R.-O. has received honoraria as a member of the advisory board participation or as a consultant for Abbvie, AstraZeneca, BMS, GSK, H3Biomedicine, Johnson & Johnson, Pfizer, Regeneron, Roche and Sanofi; has been a member of the speaker\u2019s bureau for Abbvie, BMS, GSK, Johnson & Johnson, Pfizer and Sanofi; and has received travel grants from Pfizer. A.P. has received honoraria as a member of the advisory board for Abbvie, Amgen, BMS, GSK, Johnson & Johnson, Menarini, Pfizer and Sanofi. C.D. has received honoraria for advisory roles for Amgen, BMS, GSK, Janssen, Pfizer and Sanofi. J.B. has had an advisory role or provided expert testimony for Amgen, Amicus, Galenika, Johnson & Johnson, Pfizer and Takeda; and has received honoraria from Amgen, Amicus, Galenika, Hemofarm, Johnson & Johnson, Pfizer and Takeda. D.D. has received honoraria from Amgen, BMS, GSK, Janssen, Pfizer and Sanofi; and research funding from Amgen, Celgene and Janssen. C.T. has received honoraria from Abbvie, Amgen, BMS, GSK, Janssen, Pfizer and Sanofi; and research support from Abbvie, GSK, Sanofi and Takeda. M.Be. has been a member of the advisory board for BMS, GSK, Janssen, Menarini, Pfizer, Sanofi and Takeda; a member of the speaker\u2019s bureau for BMS, GSK, Menarini, Pfizer, Sanofi and Takeda; and has received research support from Janssen. M.S.R. has had an advisory role for Abbvie, BMS, GSK, Janssen, Karyopharm, Menarini, Oncopeptides, Pfizer and Sanofi; has received honoraria from Abbvie, BMS, GSK, Janssen, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer and Sanofi; and has received research funding from BMS, Celgene, Janssen and Sanofi. M.C. has been a consultant or had an advisory role for AbbVie, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Menarini and Sanofi; and has received honoraria from Amgen, AbbVie, BMS, Celgene, GSK, Karyopharm, Janssen, Menarini and Sanofi. M.M. has been a consultant or had an advisory role for Janssen, Jazz and Sanofi; has received grants or research support from Janssen and Sanofi; has been a member of the speaker\u2019s bureau for Janssen, Jazz and Sanofi; and has received honoraria from Amgen, Janssen, Novartis, Pfizer, Sanofi and Takeda. A.S. has been a consultant for BMS, Celltrion, Haemalogix, Janssen and Rheumagen; a member of the speaker\u2019s bureau for BMS, Janssen, Pfizer, Sanofi and Thermofisher; a member of the advisory board for Antengene, BMS, Roche, Haemalogix, Janssen, Pfizer and Sanofi; received honoraria from AbbVie, Antengene, BMS, Roche, Haemalogix, Janssen, Pfizer, Sanofi and Thermofisher; and received research funding from AbbVie, Antengene, Haemalogix and Janssen. H.L. has been a consultant or a member of the speaker\u2019s bureau for Amgen, BMS, Celgene, Janssen, Pfizer, Sanofi and Takeda; and received research funding from Amgen and Sanofi. H.E. has been a consultant or had advisory roles for Amgen, BMS, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda; has received research funding from Amgen, BMS, Celgene, GSK, Janssen and Sanofi; and honoraria and travel support from Amgen, BMS, Celgene, GSK, Janssen, Novartis, Sanofi and Takeda. J.S.-M. has been a consultant for Abbvie, Amgen, BMS, Celgene, Roche, GSK, HaemaLogiX, Janssen, KaryoPharm, Merck, Novartis, Pfizer, Regeneron, Sanofi, SecuraBio and Takeda. P.S. has been a consultant or had advisory roles for BMS, Celgene, GSK, Janssen and Sanofi; has received research funding from Amgen, BMS, Celgene, Janssen, Karyopharm and Sanofi; and honoraria from BMS, Celgene, GSK, Janssen and Sanofi. E.L. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}